SPOTLIGHT: Erbitux trials produce mixed data
ImClone and Bristol-Myers Squibb report mixed results from two more studies of Erbitux. In one study of Erbitux with Best Supportive Care versus Best Supportive Care alone, the therapy demonstrated an improvement in overall survival. A separate trial comparing irinotecan to irinotecan plus Erbitux failed to demonstrate a statistically significant improvement for the Erbitux group. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
